The development of drugs is a complex task that requires high information processing ability and industry knowledge, from market research, competitor analysis to risk assessment, each link requires in-depth mining and understanding of a large number of rapidly updated pharmaceutical materials. However, the vast amount of information in pharmaceutical literature, the complexity of professional terms, and the diversity of languages often become obstacles in this process. To solve this problem, the Patsnap product development team released an ingenious new drug intelligence database named as Synapse in early 2022.
The uniqueness of this Patsnap Synapse lies in its intelligence processing mechanism – “Global Big Data AI Real-time Mining + Pharmaceutical Expert Team Verification”. This mechanism has established a real-time data update system on a global scale, covering more than 45,000 targets, 73,000 new drugs, 362,000 institutions, 800,000 clinical trials, 60 million selected literature, and 13 million drug patents. This practice allows Synapse to provide comprehensive, precise, real-time, and standardized full life-cycle data services for all industries in the biopharmaceutical industry.
Based on global patent literature, the Synapse mines early drug information and links clinical and pharmaceutical information. It is created by a team of 200 development engineers, 50 algorithm engineers and 50 pharmaceutical experts, achieving billion-level drug data seconds update. It contains basic information such as new drug data, clinical data, company pipeline, target indication, sequence data, structural data, etc., as well as derivative analysis data such as drug competition analysis, company pipeline monitoring, and sequence target affinity prediction. More emotional data includes monitoring of drugs under research in the field of tumors, TOP50 company pipeline monitoring, antibody sequence, and targeted antigen data.
The core function of Synapse is to search for data intelligence linked to modules such as new drug approval and drug details, clinical trials, core drug patents, institution pipelines, indications, and targets. Such configuration helps to meet users’ requirements for obtaining data intelligence in planning new drug pipelines, setting company strategic direction, finding opportunities for new drug development, evaluating the value of project introduction, choosing investment targets, tracking competitor strategies, developing new customers, etc.
The application scenarios are extremely wide. The Synapse can assist in the selection of R&D tracks, discover early R&D opportunities, and select appropriate targets/indications/technologies. It can act as an important tool for project value assessment, avoid early R&D risks, and be conducive to entering the market halfway with pharmaceutical companies and choosing to introduce potential drugs for joint development. When choosing investment targets, Synapse can comprehensively evaluate investment objects based on information such as institutional pipeline, technology platform, revenue, and investment. The Synapse can also generate analysis reports and continuously monitor, making it easy to understand the dynamics of research objects at anytime and anywhere.
In addition, Synapse has also demonstrated strong big data target discovery capabilities. It can provide target-related drug development situations and make target discoveries and drug predictions based on target and sequence relationship data. Such capabilities undoubtedly provide excellent data services for the entire industry chain in the bio-pharmaceutical industry, showing unprecedented possibilities.
The emergence of the Patsnap Bud Synapse means that drug development work will be more efficient and convenient, and it also means that the bio-pharmaceutical industry will gain unprecedented momentum. In the future field of biopharmaceuticals, Synapse will use leading technology advantages to realize intelligent management of the full life cycle of drug development, opening up new development prospects.